Benjamin Ashworth, MD
Interventional Pain Medicine · San Angelo, TXNPI 1255788261
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Boston Scientific at 56.4% of the total. Reporting peaked in 2020 at $5,119 and has fallen 86.3% since, to $702 in 2025.
Across 142 payments — averaging $65.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- SPR Therapeutics, Inc$919
- Abbott$816
- Medtronic$696
- Averitas Pharma Inc.$307
- Vertos Medical, Inc.$235
- plus $1K from 16 others
What the payments were for
- Grants$5,00054%
- Travel & lodging$4485%
- Food & beverage$3,81041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $5,217 |
| SPR Therapeutics, Inc | 29 | $919 |
| Abbott | 18 | $816 |
| Medtronic(2 entities) | 36 | $696 |
| Averitas Pharma Inc. | 8 | $307 |
| Vertos Medical, Inc. | 4 | $235 |
| Nevro Corp. | 9 | $227 |
| Painteq LLC | 4 | $131 |
| AbbVie | 1 | $125 |
| Collegium Pharmaceutical, Inc. | 5 | $94 |
| Nalu Medical, Inc. | 2 | $89 |
| Globus Medical | 2 | $70 |
| Biodelivery Sciences International, Inc. | 4 | $70 |
| Relievant Medsystems, Inc. | 2 | $59 |
| Pacira Pharmaceuticals Incorporated | 3 | $49 |
| Si-bone, Inc. | 2 | $48 |
| Pacira Therapeutics, Inc. | 2 | $24 |
| Curonix LLC | 1 | $21 |
| Baudax Bio Inc. | 1 | $17 |
| Hydrocision, Inc. | 1 | $16 |
| Saluda Medical Americas, Inc. | 1 | $15 |
| International Rehabilitative Sciences, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPECTRA WAVEWRITER$5,000
- PROCLAIM$408
- SPRINT PNS System$250
- mild Device Kit$135
- QULIPTA$125
- Qutenza$108
How this compares
$9,258 in reported general payments places this provider in the 55th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,057 | $25,018 |
| NucyntaTapentadol Hcl | 21 | $15,672 |
| BelbucaBuprenorphine Hcl | 15 | $12,813 |
| OxycontinOxycodone Hcl | 23 | $10,008 |
| Xtampza ErOxycodone Myristate | 22 | $6,231 |
| Hysingla ErHydrocodone Bitartrate | 13 | $4,631 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 143 | $2,916 |
| Morphine Sulfate ErMorphine Sulfate | 99 | $2,823 |
| Pregabalin | 51 | $1,232 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 37 | $947 |
| Gabapentin | 68 | $902 |
| Oxycodone Hcl | 40 | $674 |
| Morphine Sulfate | 17 | $342 |
| Tramadol Hcl | 50 | $302 |
| Duloxetine Hcl | 17 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Belbuca, Xtampza Er | $94 | $34,71658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in San Angelo
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.1M
- Chad StephensSouthlake$1M
- Ankur KhoslaShenandoah$277K
- Brian RichDecatur$245K
- Brian BruelHouston$219K
- Bolkar SahinlerLubbock$188K
- Timothy RatinoFort Worth$139K
- Genaro GutierrezAustin$125K
- Thomas WhiteShenandoah$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.